Iberdomide and mezigdomide are currently being evaluated for the treatment of patients with multiple myeloma in a number of ...

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the ...

Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed ...

A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice. The ...

Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to ...

Takeda is looking for its next shot at multiple myeloma beyond Velcade and is now previewing some early data showing partial responses in 38% of patients in one dose group for the next-in-line ...

Incidence of venous thromboembolism remains 'substantial' despite expert guidelines and newer risk prediction scores ...